Search
Close this search box.

Abstract

Nigel Phillip DanielsonEwing speaks to Sankeetha Nadarajah, Commissioning Editor

Biography

Nigel Danielson-Ewing credits his successful track record of building and commercializing fit-for-purpose solutions from his collective tenure at three benchmark companies: Vertex, Waters and Shimadzu (all MA, USA). Over the last 15 years, Dr Danielson-Ewing has amassed a diversified and cohesive skillset based on technical laboratory experience as well as business development and product management responsibilities – all implemented using strong interpersonal communication and partnerships. He appreciates the technical, business and commercial requirements needed to develop a new product and foster adoption across the industry. In his current role as director of emerging modalities at Phenomenex (CA, USA), he will work with an outstanding team of applications scientists, research engineers and project managers to implement an emerging modalities lab exploring analytical methods for mRNA and other gene therapeutics. Phenomenex, part of the Danaher family of companies, is an industry expert in surface chemistry, polymer and silica particle technology, process chemistry and equipment, column hardware and novel packing methods.

Prior to Phenomenex, Dr Danielson-Ewing was the director of product management at RedShiftBio (MA, USA). His skills were forged from a 4-year tenure at Waters as a senior product manager and business development manager and a 2-year position as a business development specialist at Shimadzu Scientific Instruments. Prior to his business roles at Shimadzu and Waters, he worked for 10 years at Vertex Pharmaceuticals, Inc., as a senior research scientist in the drug metabolism and pharmacokinetics group, researching small-molecule drug metabolism and pharmacokinetics by performing metabolite profiling, in vivo and in vitro quantification and Pgp transporter studies. He worked closely with colleagues in the medicinal chemistry, pharmacology and toxicology groups to advance compounds in multiple early-discovery and preclinical development programs. The compounds explored at Vertex spanned a panorama of biotherapeutics, including those to treat influenza, Huntington’s disease, multiple sclerosis, cystic fibrosis and other general CNS and infectious diseases.

Keywords:

  • bioanalysis
  • diversity
  • science, technology, engineering and mathematics
Scroll to Top